DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being ...

Tandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...

Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...

DexCom faces significant headwinds, including slower customer growth and increased competition. Learn more on DXCM here.

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in ...

Stock analysis is all about predictions – but as wits from Mark Twain to Yogi Berra have reminded us, predictions are hard, ...

These once-sizable artificial intelligence (AI) holdings for Google parent Alphabet have been paired down big-time over the ...

Abbott Laboratories launches its newest CGM in the U.S. on Thursday. The biosensor named Lingo is the first-ever for people without diabetes.